Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurosci ; 33(27): 10938-49, 2013 Jul 03.
Article in English | MEDLINE | ID: mdl-23825400

ABSTRACT

Working memory is an essential component of higher cognitive function, and its impairment is a core symptom of multiple CNS disorders, including schizophrenia. Neuronal mechanisms supporting working memory under normal conditions have been described and include persistent, high-frequency activity of prefrontal cortical neurons. However, little is known about the molecular and cellular basis of working memory dysfunction in the context of neuropsychiatric disorders. To elucidate synaptic and neuronal mechanisms of working memory dysfunction, we have performed a comprehensive analysis of a mouse model of schizophrenia, the forebrain-specific calcineurin knock-out mouse. Biochemical analyses of cortical tissue from these mice revealed a pronounced hyperphosphorylation of synaptic vesicle cycling proteins known to be necessary for high-frequency synaptic transmission. Examination of the synaptic vesicle cycle in calcineurin-deficient neurons demonstrated an impairment of vesicle release enhancement during periods of intense stimulation. Moreover, brain slice and in vivo electrophysiological analyses showed that loss of calcineurin leads to a gene dose-dependent disruption of high-frequency synaptic transmission and network activity in the PFC, correlating with selective working memory impairment. Finally, we showed that levels of dynamin I, a key presynaptic protein and calcineurin substrate, are significantly reduced in prefrontal cortical samples from schizophrenia patients, extending the disease relevance of our findings. Our data provide support for a model in which impaired synaptic vesicle cycling represents a critical node for disease pathologies underlying the cognitive deficits in schizophrenia.


Subject(s)
Calcineurin/deficiency , Memory Disorders/metabolism , Memory, Short-Term/physiology , Prefrontal Cortex/metabolism , Synaptic Transmission/physiology , Synaptic Vesicles/metabolism , Adult , Animals , Calcineurin/genetics , Female , Humans , Male , Memory Disorders/genetics , Mice , Mice, Knockout , Middle Aged , Nerve Net/metabolism , Organ Culture Techniques , Synaptic Vesicles/genetics
2.
Pain ; 137(1): 182-201, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18160218

ABSTRACT

Neuroinflammatory and neuroimmune mechanisms, as exemplified by infiltrating immune cells and activation of resident endothelial/glial cells, respectively, are known to be involved in the establishment and maintenance of chronic pain. An immune system pathway that may be involved in the activation of both immune and glial cells is complement. The complement pathway is made up of a large number of distinct plasma proteins which react with one another to opsonize pathogens and induce a series of inflammatory responses to help fight infection. Cleaved products and complexes produced by complement activation are responsible for a range of effects including mediation of immune infiltration, activation of phagocytes, opsonization/lysis of pathogens and injured cells, and production of vasoactive amines such as histamine and serotonin. Gene-expression microarray-analysis performed on the rat spinal nerve ligation (SNL) model of neuropathic pain revealed that multiple complement components including the C1 inhibitor, C1q alpha, beta, and gamma, C1r, C1s, C2, C3, C4, C7, and factors B, D, H, and P, were up-regulated while DAF was down-regulated. Regulation of C3 and DAF was confirmed by real-time RT-PCR and in situ hybridization. To test the hypothesis that complement plays a role in neuropathic pain, SNL rats were treated with cobra venom factor (CVF) to deplete plasma of complement component C3. Pain behavior was significantly attenuated in SNL rats treated with CVF as was complement activity at the ipsilateral dorsal root ganglia. Our results suggest the complement pathway might be a novel target for the development of neuropathic pain therapeutics.


Subject(s)
Complement Activation/physiology , Disease Models, Animal , Neuralgia/immunology , Neuralgia/physiopathology , Spinal Nerves/physiology , Animals , Complement Activation/genetics , Ligation , Neuralgia/genetics , Oligonucleotide Array Sequence Analysis/methods , Peripheral Nervous System/immunology , Peripheral Nervous System/pathology , Peripheral Nervous System/physiology , Rats , Spinal Nerves/immunology , Spinal Nerves/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...